Digestive Disease Articles & Analysis
28 news found
VisionQuest Biomedical founder and CEO Peter Soliz (PhD) has just been awarded a $1 million Commercialization Readiness Pilot Program (CRP) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (part of the US National Institutes of Health) for his work on early detection of DPN. ...
The data was presented at the annual Digestive Disease Week (DDW) conference in May. Results from a Multicenter Randomized Sham-controlled Trial of a Duodenal Jejunal Bypass Liner for the Treatment of Type 2 Diabetes Mellitus were presented by Christopher C. ...
MOUNTAIN VIEW, Calif., May 26, 2022 – G-Tech Medical, a developer of non-invasive diagnostic solutions for patients with gastrointestinal disorders, today announced that two posters were presented at Digestive Disease Week Conference held in San Diego in from May 21 through May 24. ...
About VE202 VE202 is a first-in-class defined bacterial consortium therapeutic candidate for the treatment of inflammatory bowel disease (IBD). It consists of 16 bacterial strains of the Clostridia class that were rationally selected. ...
These data were shared in oral and poster presentations at the 2022 Digestive Disease Week (DDW) Annual Meeting. “These results suggest that our investigational microbiome therapeutic, SER-109, is a potentially fast-acting intervention that can provide durable relief from recurrent C. difficile infections when administered to vulnerable patients,” ...
On the basis of clinical success and acknowledged leadership in the field of celiac disease, the organizers of the International Celiac Disease Symposium (ICDS) have invited Jack Syage PhD, CEO of ImmunogenX, to deliver a panel talk and join the Conference Faculty. ...
(Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present data from its ECOSPOR III trial of SER-109 at the Digestive Disease Week® (DDW) Annual Meeting, which is taking place May 21-24, 2022. ...
How much do you know about the development of your favorite products? What about the devices you encounter at your doctor’s office? So much of the work that goes into every single thing we use remains unseen by the user or consumer, from concept development to design to ...
This $1.6 million award from the National Institute of Diabetes and Digestive Kidney Disease (NIDDK) will allow the company to pursue additional research in the use of AVM0703 as a monotherapy and combination therapy to reverse recent onset and established Type 1 Diabetes (T1D). T1D is an autoimmune disease that destroys beta cells, the ...
CoapTech LLC announced today that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) within the National Institutes of Health (NIH) awarded the company a two-year, $1.2M R44 Small Business Innovation Research (SBIR) Phase II grant on August 29, 2019. ...
ByCoapTech
MOUNTAIN VIEW, Calif., March 15, 2022 – G-Tech Medical, a developer of non-invasive diagnostic solutions for patients with gastrointestinal disorders, today announced that two posters have been accepted for presentation at the upcoming Digestive Disease Week Conference to be held in San Diego in from May 21 through May 24. ...
Based on the results obtained from the CeliacShieldTM trial (NCT03585478) by ImmunogenX, Inc. and conducted at the Mayo Clinic, the work has been selected as a Lecture Presentation at the 2022 Digestive Disease Week® (DDW) Conference, the foremost gastroenterological event in the world, being held at the San Diego Convention Center, San Diego, CA on May ...
Located in downtown Orlando, the Orlando Health Digestive Health Institute is a national and international destination for care. The Institute is a state-of-the-art digestive diseases facility that features technologically advanced procedure rooms, preoperative and recovery bays, and support space for patients and staff. ...
Chan, head of the Division of Gastroenterology and Hepatology, Director of the Institute of Digestive Disease, the Center for Liver Health, and the Office of Global Engagement. ...
(the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced the publication of research titled "Colorectal cancer and polyp detection using a new ...
RBX2660 pivotal Phase 3 trial successfully met the primary endpoint; data presented today at Digestive Disease Week® (DDW) RBX2660 is the first microbiota-based live biotherapeutic to demonstrate efficacy as early as first recurrence of Clostridioides difficile (C. difficile) infection RBX2660 Phase 3 data add to the world’s largest and most robust ...
CoapTech Inc. announced today that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) within the National Institutes of Health (NIH) awarded CoapTech a two-year, $1.6M R44 Small Business Innovation Research (SBIR) Phase II grant on September 22, 2020 to finalize development of and trial its Pediatric PUMA-G System. ...
ByCoapTech
Addressing an Unmet Medical Need There is a great need for treatments targeting fibrosis related to Chronic Kidney Disease (CKD). Kidney fibrosis (KF) is a pathological hallmark of CKD and a major contributing factor to progression to end-stage CKD. ...
The two SBIR grants collectively totaling over $1.5 million are awarded by the NIH’s National Center for Advancing Translational Sciences and National Institute of Diabetes and Digestive and Kidney Diseases. The funded efforts include high-throughput screening, identification of new chemotypes, and preclinical animal studies. Long-term objectives of the ...
The three SBIR grants collectively totaling $2.9 million are awarded by the NIH’s National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases, and National Institute of General Medical Sciences. ...